anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Caregivers of children and young people with chronic kidney disease (CKD) face challenging circumstances on a daily basis; however, the difficulties they experienced during the COVID-19 pandemic, as well as potentially positive experiences, are not yet fully understood. The aim of this study was to explore the pandemic-related experiences of these caregivers.
METHODS: Twelve caregivers were recruited from a hospital-based pediatric renal program; eight families were posttransplant. Caregivers participated in virtual semistructured interviews conducted between March 2021 and November 2022. They provided responses to open-ended questions concerning how the pandemic affected their child with CKD, their family, and themselves. Interviews were transcribed and coded using thematic analysis.
RESULTS: Four main themes were identified: (1) Family Life, which included disruptions in routine, reduced social supports, and changes in the quality of family relationships; (2) Mental Health and Coping, which included increased anxiety and positive coping strategies; (3) Work and School Life, which included changes to work and school; and (4) Health and Health Care Systems, which included virtual health care and public health restrictions.
CONCLUSIONS: Despite facing profound challenges, caregivers identified both positive and negative aspects of their pandemic experiences. Their coping strategies highlighted individual and family resilience characteristics. Implications for health care providers, including future pandemic planning, support for the transition from in-person to virtual care, and strategies to better address barriers to resources for families of children with chronic kidney disease were discussed.
We present a case study of a patient exhibiting acquired microcephaly along with global developmental delay and drug-resistant epilepsy. Brain magnetic resonance imaging revealed distinctive features, including a Z-shaped morphology of the brainstem, volumetric reduction of white matter, diffuse thinning of the corpus callosum, and partial fusion of the cerebellar hemispheres at their most cranial portion. Whole-exome sequencing uncovered a pathogenic variant in the ARF3 gene c.200A>T, p.(Asp67Val). The neurodevelopmental disorder associated with the ARF3 gene is exceptionally rare, with only two previously documented cases in the literature. This disorder is characterized by global developmental delay and brain malformations, particularly affecting the white matter, cerebellum, and brainstem. It can also manifest as acquired microcephaly and epilepsy. These phenotypic characteristics align with Golgipathies, underscoring the significance of considering this group of conditions in relevant clinical contexts. In cases where a Z-shaped morphology of the brainstem is observed, ARF3-associated disorder should be included in the list of differential diagnoses.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other pegfilgrastim products may be misleading.

Binding antibodies to pegfilgrastim were detected using a BIAcore assay. The approximate limit of detection for this assay is 500 ng/mL. Pre-existing binding antibodies were detected in approximately 6% (51/849) of patients with metastatic breast cancer. Four of 521 pegfilgrastim-treated subjects who were negative at baseline developed binding antibodies to pegfilgrastim following treatment. None of these 4 patients had evidence of neutralizing antibodies detected using a cell-based bioassay.
The invention provides the application of honokiol in preparing medicine for treating leukemia. The molecular weight of asid leukemia is 266. 33, the chemical name is 3,5'-diallyl-4,2'-dihydroxybiphenyl, and molecular formula is C18H18O2. The prepared honokiol medicine comprises allowed medicine shaping agent and carrier. The preparation form comprises liquid, particular, tablet, slow-release, infusion, capsule and pill, capsule or injection. The toxicity of honokiol is very low, and the toxicity of anti-tumor medicine in current time is strong, so the prospect of producing anti-leukemia medicine by using honokiol is nice.
In stage Ⅳ breast cancer or recurrent breast cancer diagnosed after a curative treatment and later exhibiting distant metastasis, treatment aims are extending overall survival and improving/maintaining quality of life(QOL). The primary focus of treatment is to control systemic tumor volume, and in this regard, the introduction of novel drug treatment by years is expected to contribute to improvement of survival. However for instance, registration cohort data from France diagnosed between 2008 and 2016, categorized by diagnosis year, revealed improvements in survival only in HER2-positive breast cancer, with no such improvements observed in other subtypes. This variation appears to coincide with the introduction of novel anti-HER2 therapy, suggesting the essential need for the introduction of drugs that clearly demonstrate an extension of overall survival. Significant impacts from introduced new drugs have also been observed in other subtypes since 2017, and examining future data may confirm their reflections. Advances not only in drug development but also in cancer/host genome analysis and molecular diagnostics are allowing for more precise treatment selection and treatment changes. Enhancing treatment strategies, including proper local therapies such as surgery and radiation therapy, remains a crucial challenge.
A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a .beta. receptor blocking agent, and a use thereof are provided.  An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically acceptable salt thereof, and a .beta. receptor blocking agent, in which the .beta. receptor blocking agent is one selected from nebivolol, bisoprolol, betaxolol, celiprolol, and nadolol. A use of the pharmaceutical composition in preparation of a medicine for treating hypertension is further provided.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic sheet sufficiently closely adhering to skin when removing keratotic plugs from the skin and having an excellent ability to remove the keratotic plugs from the skin.  <P>SOLUTION: The cosmetic sheet is a cosmetic sheet having short sides and long sides. One long side has two recessed part sides so as to be linear symmetry and linear cuts are provided in a truncated chevron shape between the recessed side and the short sides. The cosmetic sheet has a skin application layer and a moisture-permeating substrate on one surface of a separator. The skin application layer is preferably composed of a wet pressure-sensitive adhesive composition containing a water-soluble polymer and an inorganic filler.  <P>COPYRIGHT: (C)2008,JPO&INPIT
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other sebelipase alfa products may be misleading.

Approximately 8% (9/106) of pediatric and adult patients with LAL deficiency developed antibodies to sebelipase alfa (anti-drug antibodies or ADA) following treatment with KANUMA across all clinical studies. Among the 9 patients who developed ADA, 2 patients were positive for neutralizing antibodies (NAb). Approximately 53% (10/19) of infants with rapidly progressive LAL deficiency developed ADA following treatment with KANUMA across all clinical studies. Among the 10 patients who developed ADA, 9 patients were positive for NAb.

Study 1: Patients with Rapidly Progressive LAL Deficiency Presenting within the First 6 Months of Life

Seven of the 9 infants with rapidly progressive disease had at least one post-treatment ADA assessment, and 4 of these 7 (57%) patients developed ADA during treatment with KANUMA. All of the 4 ADA-positive patients were determined to be positive for neutralizing antibodies that inhibit in vitro enzyme activity and/or cellular uptake of the enzyme. At the time of initial ADA positivity, 3 patients were receiving a dosage of 1 mg/kg once weekly and 1 patient was receiving a dosage of 3 mg/kg once weekly. Three of the 4 ADA-positive patients had ADA titers monitored from the initiation of treatment and developed measurable ADA titers within the first 2 months of exposure. Persistent ADA was observed in all 4 patients.

Hypersensitivity reactions occurred in all 4 of the ADA-positive patients, whereas they occurred in only 1 of the 3 ADA-negative patients. None of the patients discontinued treatment. In 1 patient, decreased growth velocity in a setting of neutralizing antibodies to KANUMA was observed.

Study 2: Pediatric and Adult Patients with LAL Deficiency

Five of 35 (14%) KANUMA-treated pediatric and adult patients who completed the 20-week double-blind period of study treatment developed ADA. All patients were receiving 1 mg/kg once every other week. All 5 ADA-positive patients first developed measurable ADA titers within the first 3 months of exposure. Two of the 5 ADA-positive patients had a measurable ADA titer at only one time point. In the 3 patients with measurable ADA titers at multiple time points, ADA titers decreased to undetectable levels during continued treatment. Two patients developed in vitro neutralizing antibodies during the open-label extension phase after 20 weeks and 52 weeks of treatment with KANUMA, respectively. There is no clear association between the development of ADA and decreased efficacy in pediatric and adult patients treated with KANUMA.
PURPOSE: To investigate whether preoperative spectral CT quantitative parameters can assess perineural invasion (PNI) status in rectal cancer.
METHODS: Sixty-two patients diagnosed with rectal cancer who underwent preoperative spectral CT were retrospectively enrolled and divided into positive and negative PNI groups according to histopathologic results. The CT attenuation value (HU) of virtual monochromatic images (40-70 keV), spectral curve slope (K(HU)), effective atomic number (Zeff), and iodine concentration (IC) from spectral CT were compared between these two groups using t test or rank sum test. A nomogram was established by incorporating the independent predictors to assess the overall diagnostic efficacy. The area under the ROC curves (AUCs) were compared using the DeLong test.
RESULTS: The preoperative spectral CT parameters (40-70 keV attenuation, K(HU), Zeff, and IC) were significantly higher in the PNI-positive group compared to the PNI-negative group (all p < 0.05). The highest predictive efficiency of PNI was observed at 40 keV attenuation, with an area under the curve (AUC), sensitivity, specificity, and accuracy of 0.847, 81.8%, 72.5%, and 75.8%, respectively. Binary logistic regression demonstrated that the clinical feature (cN stage) and 40 keV attenuation were independent predictors of PNI status. The nomogram incorporating these two predictors (cN stage and 40 keV attenuation) exhibited the best evaluation efficacy, with an AUC, sensitivity, specificity, and accuracy of 0.885, 86.4%, 77.5%, and 80.6%.
CONCLUSION: Spectral CT quantitative parameters proved valuable in the preoperative assessment of PNI status in rectal cancer patients. The combination of spectral CT parameters and clinical features could further enhance the diagnostic efficiency.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to otolaryngology, and can be used for treatment of sensorineural deafness of various etiology. For this purpose impact by pulse laser radiation through curved endoprobe is performed. Preliminarily carried out is anesthesis os lower and medial nasal ways and nasopharynx of irradiated side with 10% solution of lidocain by method of dispersion in direction from front to back through vestibule of nose. After that in lower nasal way introduced is polymer catheter, which fills common nasal way to the level of medial nasal turbinate. After that by channel, composed by medial nasal turbinate on one side and polymer catheter on the other side, introduced is endoprobe to the depth of contact with posterior wall, placing point of endoprobe irradiation at angle 25-45 degrees in horizontal plane 1.0-1.5 cm higher than pharyngeal orifice of auditory tube. Radiation is performed for 2-15 minutes in pulse mode with pulse power 5.5 W, pulse duration 60 ms, pulse frequency 6 Hz, with 30 sec pulse cycles. ^ EFFECT: method ensures stable improvement of auditory function, makes it possible to exclude injuries of mucosa and angiospasm, resulting in improvement of feeding and metabolic processes in cells of nerve fibres of auditory nerve. ^ 2 cl, 1 ex
PURPOSE:To compress considerably image data by calculating the mean value of image data in every group and difference values between the mean value and respective data, and expressing the difference values with bits less than the mean value. CONSTITUTION:Image data is arrayed and stored in video memory 5, picture element by element. When operation starts, image data of 9 picture elements is read out of the video memory 5. Then, the total value of the data of 9 picture elements is calculated. This total value is divided by 9 to calculate the mean value. This mean value is stored in a storage medium 9. An internal counter of a CPU8 which specifies a row and a column of picture elements in a group is reset to 0. Then, difference value arithmetic is carried out to decide whether the absolute value of the difference value is larger than a set value or not, and the difference value is written in a storage area following the mean value in the storage medium 9 unless the difference value overflows. This difference value is written in the storage area following the mean value in the storage medium 9. This storing method is employed to compress considerably and store data.
Necrosis in solid tumors is commonly associated with poor prognostic but how these lesions expand remains unclear. Studies have found that neutrophils associate with and contribute to necrosis development in glioblastoma by inducing tumor cell ferroptosis through transferring myeloperoxidase-containing granules. However, the mechanism of neutrophilic granule transfer remains elusive. We performed an unbiased small molecule screen and found that statins inhibit neutrophil-induced tumor cell death by blocking the neutrophilic granule transfer. Further, we identified a novel process wherein neutrophils are engulfed by tumor cells before releasing myeloperoxidase-containing contents into tumor cells. This neutrophil engulfment is initiated by integrin-mediated adhesion, and further mediated by LC3-associated phagocytosis (LAP), which can be blocked by inhibiting the Vps34-UVRAG-RUBCN-containing PI3K complex. Myeloperoxidase inhibition or Vps34 depletion resulted in reduced necrosis formation and prolonged mouse survival in an orthotopic glioblastoma mouse model. Thus, our study unveils a critical role for LAP-mediated neutrophil internalization in facilitating the transfer of neutrophilic granules, which in turn triggers tumor cell death and necrosis expansion. Targeting this process holds promise for improving glioblastoma prognosis.
Greenshell™ mussels (Perna canaliculus) are endemic to New Zealand and support the largest aquaculture industry in the country. Photobacterium swingsii was isolated and identified from moribund P. canaliculus mussels following a mass mortality event. In this study, a challenge experiment was used to characterise, detect, and quantify P. swingsii in adult P. canaliculus following pathogen exposure via injection into the adductor muscle. A positive control (heat-killed P. swingsii injection) was included to account for the effects of injection and inactive bacterial exposure. Survival of control and infected mussels remained 100% during 72-hour monitoring period. Haemolymph was sampled for bacterial colony counts and haemocyte flow cytometry analyses; histology sections were obtained and processed for histopathological assessments; and adductor muscle, gill, digestive gland were sampled for quantitative polymerase chain reaction (PCR) analyses, all conducted at 12, 24, 48 h post-challenge (hpc). The most profound effects of bacterial injection on mussels were seen at 48 hpc, where mussel mortality, haemocyte counts and haemolymph bacterial colony forming were the highest. The quantification of P. swingsii via qPCR showed highest levels of bacterial DNA at 12 hpc in the adductor muscle, gill, and digestive gland. Histopathological observations suggested a non-specific inflammatory response in all mussels associated with a general stress response. This study highlights the physiological effects of P. swingsii infection in P. canaliculus mussels and provides histopathological insight into the tissue injury caused by the action of injection into the adductor muscle. The multi-technique methods used in this study can be applied for use in early surveillance programs of bacterial infection on mussel farms.
The effect of a new JNK inhibitor IQ-1 (11H-indeno[1,2-b]quinoxalin-11-one oxime) was studied in male Wistar rats in a model of acute myocardial ischemia/reperfusion. Area at risk and myocardial infarct zones were studied in two series of experiments: 16 h after a single dose of IQ-1 (25 mg/kg intraperitoneally during cardiac ischemia) and on day 5 after its course administration (25 mg/kg intraperitoneally during cardiac ischemia and daily over 4 days). On day 5 after ischemia/reperfusion, cardiodynamic indicators were also studied: systolic, end-diastolic, and minimum pressure in the left ventricle, stress-time index, as well as the maximum rates of pressure rise and fall in the left ventricle (+dP/dtmax and -dP/dtmax). In 16 h after ischemia/reperfusion, the infarct area in the control was 24±2% of the total area of the sections, while after administration of IQ-1 this parameter was 14±1% (p<0.05). On day 5, the infarct area in the control group was 25±1% of the total area of myocardial sections. A course of IQ-1 administration led to a significant reduction in the infarct area to 10±2% of the total area of myocardial slices. Course administration of IQ-1 led to improvement in contractile function and weakening of the diastolic dysfunction of the left ventricle: systolic pressure in the left ventricle increased by 20%, +dP/dtmax by 23%, voltage-time index by 12%, -dP/dtmax by 43%, and the minimum pressure in the left ventricle decreased by 3.4 times.
The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
The present invention, it was confirmed that a pharmaceutical composition and a health functional food composition for alleviating eye fatigue containing, as active ingredients, compounds, particularly, luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide isolated from a Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo leaf extract have an effect of alleviating eye fatigue by increasing the contents of NO and cGMP associated with relaxation of ciliary smooth muscle cells isolated from rat's eyes and decreasing the content of [Ca2+]i, and increasing cGMP which is a factor associated with relaxation of the ciliary smooth muscle through an animal experiment. As a result, the luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide compounds extracted from Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo may be usefully used as a pharmaceutical composition and a health functional food composition having an eye fatigue alleviating effect as a Korean natural resource.
The invention discloses a duck tembusu virus E protein truncation gene, a recombinant duck plague virus, a construction method and application. The nucleotide sequence of the duck tembusu virus E protein truncation body gene is shown in SEQ ID No. 4. A recombinant duck plague virus, wherein the gene group of the recombinant duck plague virus is inserted with the gene of the E protein truncation body of the duck tembusu virus. The invention obtains the truncated gene of the E protein of the duck tembusu virus through screening, a new recombinant duck plague virus is obtained by inserting the E protein truncated gene into the genome of the recombinant duck plague virus, and the E protein truncated gene obtains high-efficiency expression after infecting CEFs cells. The recombinant duck plague virus inserted with the E protein truncation gene can be used for preparing a duck plague virus and duck tembusu virus bivalent vaccine.
The present invention relates to an improved controlled release system that can encapsulate different flavors, sensory markers, and active ingredients, or combinations of flavors, sensory markers and various active ingredients and release multiple active ingredients in a consecutive manner, one after the other. The controlled delivery system of the present invention is substantially free-flowing powder formed of solid hydrophobic nanospheres that are encapsulated in a moisture sensitive microspheres. The flavors, and active ingredients encapsulated in the hydrophobic nanospheres, in the water sensitive microsphere, or in both the nano and the microsphere. The flavors and active ingredients encapsulated in the nanospheres can be the same or different from those encapsulated in the microspheres. The encapsulation of different flavors or active agents in the various components of the system, such as nanospheres and microspheres, provides flavor transition (change in flavor character) during the use of the products. The controlled release system of the present invention enhances the stability and bioavailability of wide range of flavors, sensory markers, and other active ingredients, prolong their residence time in the oral cavity, control their release characteristics, and prolong the sensation of flavors and other sensory markers in the mouth to provide long lasting organoleptic perception or long lasting mouthfeel. The invention further relates oral care, food products, and beverages comprising the controlled release system of the present invention.